Skip to main navigation Skip to search Skip to main content

Homozygous familial hypercholesterolemia with an update on cholesterol management

  • Anju J J Velvet
  • , Handrean Soran
  • , Bernard Clarke
  • , Manish Motwani
  • , Farzin F Ordoubadi
  • , Matthew J Daniels
  • Manchester University NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

Abstract

Familial hypercholesterolemia (FH) is an autosomal dominant condition that increases the risk of premature cardiovascular disease. Despite advances in treatment, it remains under detected and under treated. As an inherited condition, it poses a risk to the patient and family members. Most cases are due to defective low-density lipoprotein receptor (LDLR) activity. Heterozygous mutations are common (1:250–1:300). Homozygous FH is very rare (2–3 in a million), with higher circulating cholesterol levels and a poorer cardiovascular prognosis. We present the management of a case of homozygous hypercholesterolemia due to homozygous LDLR mutation. The patient subsequently developed severe coronary artery and aortic valve disease despite aggressive lipid-lowering therapy. We review advanced lipid management options that include lipoprotein apheresis, Proprotein Convertase Subtilisin/Kexin type 9 inhibition, and the microsomal triglyceride transfer protein inhibitor lomitapide.
Original languageEnglish
JournalOxford Medical Case Reports
Volume2020
Issue number9
DOIs
Publication statusPublished - 22 Sept 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Homozygous familial hypercholesterolemia with an update on cholesterol management'. Together they form a unique fingerprint.

Cite this